Baird Medical Investment’s (BDMD) “Sell (D)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d) rating on shares of Baird Medical Investment (NASDAQ:BDMD) in a research report report published on Thursday morning,Weiss Ratings reports.

Separately, Wall Street Zen cut Baird Medical Investment from a “hold” rating to a “sell” rating in a report on Monday, July 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Baird Medical Investment currently has an average rating of “Sell”.

Baird Medical Investment Trading Down 6.4%

Shares of NASDAQ BDMD opened at $1.31 on Thursday. The firm has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $3.42. Baird Medical Investment has a 52 week low of $1.05 and a 52 week high of $12.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BDMD. XTX Topco Ltd acquired a new position in shares of Baird Medical Investment in the first quarter worth $111,000. Geode Capital Management LLC increased its holdings in shares of Baird Medical Investment by 59.7% in the 2nd quarter. Geode Capital Management LLC now owns 25,442 shares of the company’s stock valued at $93,000 after acquiring an additional 9,511 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Baird Medical Investment in the 2nd quarter valued at about $142,000. Institutional investors and hedge funds own 19.78% of the company’s stock.

Baird Medical Investment Company Profile

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.